
CORRIGENDUM

Sirtuins — novel therapeutic targets to treat age-associated diseases

Siva Lavu, Olivier Boss, Peter J. Elliott & Philip D. Lambert

Nature Reviews Drug Discovery 7, 841–853 (2008) | doi:10.1038/nrd2665

The structure of suramin on page 844 is incorrect; the correct structure is shown below:



The following paragraph and associated reference were mistakenly omitted from the discussion of the role of sirtuins in cancer on page 850:

"In a recent effort to identify activators of p53 in a mammalian cell-based screen, a reporter construct was placed under the regulation of a p53 target promoter, and active compounds that increased reporter activity were selected from the library screen. This strategy led to the identification of a series of compounds called tenovins¹."

 Lain, S. et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13, 454–463 (2008).